StreetInsider.com News Articles

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Thu, 23 Jul 2026 09:05:00 -0400

SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter of 2026.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Thu, 23 Jul 2026 09:05:00 -0400

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website

Myriad Genetics launches four-in-one prenatal genetic screen

Tue, 21 Jul 2026 09:05:52 -0400

Myriad Genetics, Inc. (NASDAQ: MYGN) announced the commercial launch of its FirstGene Multiple Prenatal Screen, a lab test that runs four prenatal genetic screens simultaneously from a single blood draw, available as early as eight weeks gestation.

The test combines fetal chromosome screening, fetal single-gene screening, patient carrier screening, and fetal RhD screening into one integrated report. Results are expected to be delivered in approximately 10 days, according to the company's press release.

The fetal chromosome screen assesses risk for conditions including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), sex chromosome aneuploidies, and 22q11.2 microdeletion (DiGeorge syndrome).

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Tue, 21 Jul 2026 09:05:00 -0400

The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestation

SALT LAKE CITY, July 21, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the full commercial launch of FirstGene ^® Multiple Prenatal Screen, the only lab test that runs four prenatal genetic screens simultaneously from a single blood draw as early as eight weeks gestation.^* The FirstGene screen delivers fetal chromosome screening, fetal single-gene screening, patient carrier screening and

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Tue, 21 Jul 2026 09:05:00 -0400

The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestation

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

Thu, 02 Jul 2026 09:05:00 -0400

Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories

SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest individual-patient-data meta-analysis of Prolaris to date, showing the Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for patients with localized prostate cancer. This evidence supports the role of the Prolaris Biopsy Test in localized prostate cancer risk stratification to help inform initial

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

Thu, 02 Jul 2026 09:05:00 -0400

Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories

Form 4 MYRIAD GENETICS INC For: Jun 23 Filed by: Skovronsky Daniel

Tue, 23 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260623/26679810.html

Form 4 MYRIAD GENETICS INC For: Jun 23 Filed by: Skovronsky Daniel

Tue, 23 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260623/26679810.html

Myriad Genetics expands Precise MRD cancer test to three tumor types

Tue, 23 Jun 2026 09:05:55 -0400

Myriad Genetics (NASDAQ: MYGN) announced the expanded availability of its Precise MRD test to patients with breast, colorectal, and renal cancers, according to a company press release. More than 6 million people in the U.S. are living with these cancers, according to the National Cancer Institute.

Precise MRD is a whole-genome sequencing-based assay that tracks up to 1,000 patient-specific variants to measure circulating tumor DNA (ctDNA). The test is designed for use at multiple points in cancer care, including neoadjuvant monitoring, post-surgical assessment, and long-term surveillance.

Alongside the expansion, Myriad published results from the prospective, multi-center MONITOR-Breast study in Future Oncology. The

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Tue, 23 Jun 2026 09:05:00 -0400

Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD

SALT LAKE CITY, June 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients undergoing treatment and surveillance for breast, colorectal and renal cancers. More than 6 million individuals are living with these cancers in the U.S., representing a significant expansion in access to Myriad’s ultrasensitive Precise MRD test¹.

Precise MRD is a next-generation, ultrasensitive, whole-genome sequencing-based assay that generates a personalized

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Tue, 23 Jun 2026 09:05:00 -0400

Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD

Precise MRD is a next-generation, ultrasensitive, whole-genome sequencing-based assay that generates a personalized

Myriad Genetics board member Skovronsky resigns

Tue, 23 Jun 2026 08:36:07 -0400

Daniel M. Skovronsky, M.D., Ph.D., a member of the board of directors of Myriad Genetics (NASDAQ: MYGN), resigned from his position effective June 17, 2026.

According to a company statement, Skovronsky's departure was not the result of any disagreement with the company or any matter relating to its operations, policies, or practices.

Myriad Genetics board member Skovronsky resigns

Tue, 23 Jun 2026 08:36:07 -0400

Daniel M. Skovronsky, M.D., Ph.D., a member of the board of directors of Myriad Genetics (NASDAQ: MYGN), resigned from his position effective June 17, 2026.

According to a company statement, Skovronsky's departure was not the result of any disagreement with the company or any matter relating to its operations, policies, or practices.

Form 8-K MYRIAD GENETICS INC For: Jun 17

Tue, 23 Jun 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260623/26676500.html

Form 8-K MYRIAD GENETICS INC For: Jun 17

Tue, 23 Jun 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260623/26676500.html

Form 4 MYRIAD GENETICS INC For: Jun 11 Filed by: Donnelly Brian J

Fri, 12 Jun 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26642379.html

Form 4 MYRIAD GENETICS INC For: Jun 11 Filed by: Donnelly Brian J

Fri, 12 Jun 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26642379.html

Form 4 MYRIAD GENETICS INC For: Jun 11 Filed by: Raha Samraat S.

Fri, 12 Jun 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26642381.html

Form 4 MYRIAD GENETICS INC For: Jun 11 Filed by: Raha Samraat S.

Fri, 12 Jun 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26642381.html

TD Cowen notes short interest shifts in life science tools stocks

Wed, 10 Jun 2026 10:50:16 -0400